Natural product like “shikonin” might be a hope for Breast cancer cure

[1] R. Yuan, Y. Hou, W. Sun, J. Yu, X. Liu, Y. Niu, J.J. Lu, and X. Chen, “Natural products to prevent drug resistance in cancer chemotherapy: a review”, Annals of the New York Academy of Sciences, 1401, 2017, 19-27 DOI: 10.1111/nyas.13387.10.1111/nyas.1338728891091Open DOISearch in Google Scholar

[2] M.S. Donepudi, K. Kondapalli, S.J. Amos, and P. Venkanteshan, “Breast cancer statistics and markers”, Journal of cancer research and therapeutics, Vol. 10, 506, 2014. DOI: 10.4103/0973-1482.137927.Search in Google Scholar

[3] J. Xu, K. Koizumi, M. Liu, Y. Mizuno, M. Suzaki, H. Iitsuka, A. Inujima, M. Fujimoto, N. Shibahara, and Y. Shimada, “Shikonin induces an anti tumor effect on murine mammary cancer via p38 dependent apoptosis”, Oncology reports, Vol. 41, 2020-2026, 2019. DOI: org/10.3892/or.2019.6966.10.3892/or.2019.696630664166Open DOISearch in Google Scholar

[4] R. Thakur, R. Trivedi, N. Rastogi, M. Singh, and D.P. Mishra, “Inhibition of STAT3, FAK and Src mediated signaling reduces cancer stem cell load, tumorigenic potential and metastasis in breast cancer”, Scientific reports, Vol. 5, 10194, 2015. DOI: 10.1038/srep10194.10.1038/srep10194443148025973915Open DOISearch in Google Scholar

[5] K.H. Lin, M.Y. Huang, W.C. Cheng, S.C. Wang, S.H. Fang, H.P. Tu, C.C. Su, Y.L. Hung, P.L. Liu, C.S. Chen, and Y.T. Wang, “RNA-seq transcriptome analysis of breast cancer cell lines under shikonin treatment”, Scientific reports, Vol. 8, 2672, 2018. DOI: 10.1038/s41598-018-21065-x.10.1038/s41598-018-21065-x580569229422643Search in Google Scholar

[6] A.G. Waks, and E.P. Winer, “Breast cancer treatment: a review”, Jama, Vol. 321, 288-300, 2019. DOI: 10.1001/jama.2018.19323.10.1001/jama.2018.1932330667505Open DOISearch in Google Scholar

[7] C.E. DeSantis, J. Ma, A. Goding Sauer, L.A. Newman, and A. Jemal, “Breast cancer statistics, 2017, racial disparity in mortality by state”, CA: a cancer journal for clinicians, Vol. 67, 439-448, 2017. DOI: org/10.3322/caac.21412.10.3322/caac.2141228972651Open DOISearch in Google Scholar

[8] J.C. Boulos, M. Rahama, M.E.F. Hegazy, and T. Efferth, “Shikonin derivatives for cancer prevention and therapy”, Cancer letters, Vol. 459, 248-267, 2019. DOI: org/10.1016/j.canlet.2019.04.033.10.1016/j.canlet.2019.04.03331132429Search in Google Scholar

[9] X. Liu, and G. Sun, “Shikonin enhances Adriamycin antitumor effects by inhibiting efflux pumps in A549 cells”, Oncology letters, Vol. 14, 4270-4276, 2017. DOI: org/10.3892/ol.2017.6702.10.3892/ol.2017.6702560411628943938Open DOISearch in Google Scholar

[10] J.E. Visvader, and J. Stingl, “Mammary stem cells and the differentiation hierarchy: current status and perspectives”, Genes & development, Vol. 28, 1143-1158, 2014. DOI: 10.1101/gad.242511.114.24888586Search in Google Scholar

[11] A.S. Cleary, T.L. Leonard, S.A. Gestl, and E.J. Gunther, “Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers”, Nature, Vol. 508, 113, 2014. DOI: org/10.1038/nature13187.10.1038/13187Open DOISearch in Google Scholar

[12] N. Duru, R. Gernapudi, and Q. Zhou, “Chemopreventive activities of shikonin in breast cancer”, Biochem Pharmacol., Vol. 3, 163, 2014. DOI: 10.4172/2167-0501.1000e163.10.4172/2167-0501.1000e163Open DOISearch in Google Scholar

[13] N. Yingkun, Z. Lvsong, and Y. Huimin, “Shikonin inhibits the proliferation and induces the apoptosis of human HepG2 cells”, Canadian journal of physiology and pharmacology, Vol. 88, 1138-1146, 2010. DOI: org/10.1139/Y10-085.10.1139/Y10-085Open DOISearch in Google Scholar

[14] Z. Wu, L. Wu, L. Li, S.I. Tashiro, S. Onodera, and T. Ikejima, “p53-mediated cell cycle arrest and apoptosis induced by shikonin via a caspase-9-dependent mechanism in human malignant melanoma A375-S2 cells”, Journal of pharmacological sciences, Vol. 94, 166-176, 2004. DOI: org/10.1254/jphs.94.166.10.1254/jphs.94.166Open DOISearch in Google Scholar

[15] H. Wu, J. Xie, Q. Pan, B. Wang, D. Hu, and X. Hu, “Anticancer agent shikonin is an incompetent inducer of cancer drug resistance”, PloS one, Vol. 8, 52706, 2013. DOI: org/10.1371/journal.pone.0052706.Search in Google Scholar

[16] B. Wiench, T. Eichhorn, M. Paulsen, and T. Efferth, “Shikonin directly targets mitochondria and causes mitochondrial dysfunction in cancer cells”, Evidence-Based Complementary and Alternative Medicine, 2012. DOI: org/10.1155/2012/726025.10.1155/2012/726025Open DOISearch in Google Scholar

[17] S.M. Pierce, A. Recht, T.I. Lingos, A. Abner, F. Vicini, B. Silver, A. Herzog, and J.R. Harris, “Long-term radiation complications following conservative surgery (CS) and radiation therapy (RT) in patients with early stage breast cancer”, International Journal of Radiation Oncology* Biology* Physics., Vol. 23, 915-923, 1992. DOI: org/10.1016/0360-3016 (92)90895-O.10.1016/0360-3016(92)90895-OOpen DOISearch in Google Scholar

[18] P. Fumoleau, R. Largillier, C. Clippe, V. Dieras, H. Orfeuvre, T. Lesimple, S. Culine, B. Audhuy, D. Serin, H. Cure, and E. Vuillemin, “Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline-and taxane-pretreated metastatic breast cancer”, European Journal of Cancer, Vol. 40, 536-542, 2004. DOI: org/10.1016/j.ejca.2003.11.007.10.1016/j.ejca.2003.11.007Open DOISearch in Google Scholar

[19] R.R. Love, H. Leventhal, D.V. Easterling, and D.R. 1989. “Nerenz, Side effects and emotional distress during cancer chemotherapy”, Cancer, Vol. 63, 604-612, 1989. DOI: org/10.1002/1097-0142 (19890201)63:3<604.10.1002/1097-0142(19890201)63:3<604Open DOISearch in Google Scholar

[20] C.H. Chen, M.L. Lin, P.L. Ong, and J.T. Yang, “Novel multiple apoptotic mechanism of shikonin in human glioma cells”, Annals of surgical oncology, Vol. 19, 3097-3106, 2012. DOI: org/10.1245/s10434-012-2324-4.10.1245/s10434-012-2324-422446899Open DOISearch in Google Scholar

[21] W. Li, J. Liu, K. Jackson, R. Shi, and Y. Zhao, “Sensitizing the therapeutic efficacy of taxol with shikonin in human breast cancer cells”, PloS one, Vol. 9, 2014. e94079 DOI: org/10.1371/journal.pone.0094079.10.1371/journal.pone.0094079397798124710512Search in Google Scholar

[22] L. Jia, Z. Zhu, H. Li, and Y. Li, “Shikonin inhibits proliferation, migration, invasion and promotes apoptosis in NCI-N87 cells via inhibition of PI3K/AKT signal pathway”, Artificial cells, nanomedicine, and biotechnology, Vol. 47, 2662-2669, 2019. org/10.1080/21691401.2019.1632870.10.1080/21691401.2019.163287031257936Search in Google Scholar

[23] J. Chen, J. Xie, Z. Jiang, B. Wang, Y. Wang, and X. Hu, “Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2”, Oncogene, Vol. 30, 4297, 2011. DOI: org/10.1038/onc.2011.137.10.1038/onc.2011.13721516121Open DOISearch in Google Scholar

[24] Z. Shahsavari, F. Karami-Tehrani, S. Salami, and M. Ghasemzadeh, “RIP1K and RIP3K provoked by shikonin induce cell cycle arrest in the triple negative breast cancer cell line, MDA-MB-468: necroptosis as a desperate programmed suicide pathway”, Tumor Biology, Vol. 37, 4479-4491, 2016. DOI: org/10.1007/s13277-015-4258-5.10.1007/s13277-015-4258-526496737Open DOISearch in Google Scholar

[25] Y. Yao, and Q.A. Zhou, “Novel antiestrogen agent Shikonin inhibits estrogen-dependent gene transcription in human breast cancer cells”, Breast cancer research and treatment, Vol. 12, 233-240, 2010. DOI: org/10.1007/s10549-009-0547-2.10.1007/s10549-009-0547-219760501Open DOISearch in Google Scholar

[26] S. Zhang, Q. Gao, W. Li, L. Zhu, Q. Shang, S. Feng, J. Jia, Q. Jia, S. Shen, and Z. Su, “Shikonin inhibits cancer cell cycling by targeting Cdc25s”, BMC cancer., Vol. 19, 20, 2019. DOI: org/10.1186/s12885-018-5220-x10.1186/s12885-018-5220-x632379330616572Open DOISearch in Google Scholar

[27] Y. Chen, Z.Y. Chen, L. Chen, J.Y. Zhang, L.Y. Fu, L. Tao, Y. Zhang, X.X. Hu, and X.C. Shen, “Shikonin inhibits triple-negative breast cancer-cell metastasis by reversing the epithelial-to-mesenchymal transition via glycogen synthase kinase 3β-regulated suppression of β-catenin signaling”, Biochemical pharmacology, Vol. 166, 33-45, 2019. DOI: org/10.1016/j.bcp.2019.05.001.10.1016/j.bcp.2019.05.00131071331Open DOISearch in Google Scholar

[28] Z. Zhong, W.W. Qiang, W. Tan, H. Zhang, S. Wang, C. Wang, W. Qiang, and Y. Wang, “Chinese herbs interfering with cancer reprogramming metabolism”, Evidence-Based Complementary and Alternative Medicine, 2016. DOI: org/10.1155/2016/9282813.10.1155/2016/9282813487599527242914Open DOISearch in Google Scholar

[29] R. Gernapudi, Y. Yao, Y. Zhang, B. Wolfson, S. Roy, N. Duru, G. Eades, P. Yang, and Q. Zhou, “Targeting exosomes from preadipocytes inhibits preadipocyte to cancer stem cell signaling in early-stage breast cancer”, Breast cancer research and treatment, Vol. 150, 685-695, 2015. DOI: org/10.1007/s10549-015-3326-2.10.1007/s10549-015-3326-2438548325783182Open DOISearch in Google Scholar

[30] W.R. Huang, Y. Zhang, and X. Tang, “Shikonin inhibits the proliferation of human lens epithelial cells by inducing apoptosis through ROS and caspase-dependent pathway”, Molecules, Vol. 19, 7785-7797, 2014. DOI: org/10.3390/molecules19067785.10.3390/19067785Open DOISearch in Google Scholar

[31] R. Tian, Y. Li, and M. Gao, “Shikonin causes cell-cycle arrest and induces apoptosis by regulating the EGFR–NF-κB signalling pathway in human epidermoid carcinoma A431 cells”, Bioscience reports, Vol. 35, e00189, 2015. DOI: 10.1042/BSR20150002.10.1042/BSR20150002441301925720435Open DOISearch in Google Scholar

[32] Y. Li, H. Lu, Y. Gu, Z. Ning, T. Cao, C. Chen, C. Hu, and M. Tao, “Enhancement of NK cells proliferation and function by Shikonin”, Immunopharmacology and immunotoxicology, Vol. 39, 124-130, 2017. DOI: org/10.1080/08923973.2017.1299174.10.1080/08923973.2017.129917428303727Open DOISearch in Google Scholar

[33] Y.D. Jin, Y. Ren, M.W. Wu, P. Chen, and J. Lu, “Effect of shikonin on multidrug resistance in HepG2: The role of SIRT1”, Pharmaceutical biology, Vol. 53, 1016-1021, 2015. DOI: org/10.3109/13880209.2014.952836.10.3109/13880209.2014.95283625471124Open DOISearch in Google Scholar

[34] S.Y. Jang, D. Hong, S.Y. Jeong, and J.H. Kim, “Shikonin causes apoptosis by up-regulating p73 and down-regulating ICBP90 in human cancer cells”, Biochemical and biophysical research communications, Vol. 465, 71-76, 2015. DOI: org/10.1016/j.bbrc.2015.07.131.10.1016/j.bbrc.2015.07.13126235879Open DOISearch in Google Scholar

[35] C.H. Zhang, J. Wang, L.X. Zhang, Y.H. Lu, T.H. Ji, L. Xu, and L.J. Ling, “Shikonin reduce tamoxifen resistance through long non-coding RNA uc. 57”, Oncotarget, Vol. 8, 88658, 2017. DOI: 10.18632/oncotarget.20809.10.18632/oncotarget.20809568763529179465Search in Google Scholar

[36] K. Liew, P.V.C. Yong, Y.M. Lim, V. Navaratnam, and A.S.H. Ho, “2-Methoxy-1, 4-Naphthoquinone (MNQ) suppresses the invasion and migration of a human metastatic breast cancer cell line (MDA-MB-231)”, Toxicology in Vitro, Vol. 28, 335-339, 2014. DOI: org/10.1016/j.tiv.2013.11.008.10.1016/j.tiv.2013.11.00824291160Open DOISearch in Google Scholar

[37] S.Y. Jang, J.K. Lee, E.H. Jang, S.Y. Jeong, and J.H. Kim, “Shikonin blocks migration and invasion of human breast cancer cells through inhibition of matrix metalloproteinase-9 activation”, Oncology reports, Vol. 31, 2827-2833, 2014. DOI: org/10.3892/or.2014.3159.10.3892/or.2014.315924789371Open DOISearch in Google Scholar

[38] Z. Shahsavari, F. Karami-Tehrani, and S. Salami, “Shikonin induced necroptosis via reactive oxygen species in the T-47D breast cancer cell line”, Asian Pac J Cancer Prev., Vol. 16, 7261-7266, 2015. DOI: org/10.7314/APJCP.2015.16.16.7261.10.7314/APJCP.2015.16.16.7261Open DOISearch in Google Scholar

[39] Q. Yang, S. Li, Z. Fu, B. Lin, Z. Zhou, Z. Wang, Y. Hua, and Z. Cai, “Shikonin promotes adriamycin induced apoptosis by upregulating caspase 3 and caspase 8 in osteosarcoma”, Molecular medicine reports, Vol. 16, 1347-1352, 2017. DOI: org/10.3892/mmr.2017.6729.10.3892/mmr.2017.6729556208728627658Search in Google Scholar

[40] C. Holohan, S. Van Schaeybroeck, D.B. Longley, and P.G. Johnston, “Cancer drug resistance: an evolving paradigm”, Nature Reviews Cancer, Vol. 13, 714, 2013. DOI: org/10.1038/nrc3599.10.1038/nrc359924060863Open DOISearch in Google Scholar

[41] H.B. Xu, L. Li, J. Fu, X.P. Mao, and L.Z. Xu, “Reversion of multidrug resistance in a chemoresistant human breast cancer cell line by β-elemene”, Pharmacology, Vol. 89, 303-312, 2012. DOI: org/10.1159/000337178.10.1159/00033717822573000Open DOISearch in Google Scholar